{"nctId":"NCT00252720","briefTitle":"DIabetic Retinopathy Candesartan Trials.","startDateStruct":{"date":"2001-08"},"conditions":["Type 1 Diabetes"],"count":1850,"armGroups":[{"label":"candesartan","type":"EXPERIMENTAL","interventionNames":["Drug: candesartan"]},{"label":"placebo","type":"NO_INTERVENTION","interventionNames":[]}],"interventions":[{"name":"candesartan","otherNames":["ATACAND"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female aged 18 - 55 years with type 1 diabetes diagnosed before age of 36 years and in need for continuous insulin treatment within 1 year of diagnosis of diabetes are included.\n* Duration of diabetes for \\> 1 year and \\< 20 years with stable diabetic therapy within last 6 months.\n* Patients with untreated resting mean sitting SBP \\< 130 mmHg, mean sitting DBP \\< 85 mmHg and with retinal photograph grading level \\> 20/10 up to \\< 47/47 (on ETDRS severity scale).\n\nExclusion Criteria:\n\n* Patients with the following conditions are excluded from participation on the study:\n* Cataract or media opacity of a degree which precludes taking gradable retinal photographs\n* Angle closure glaucoma, which precludes pharmacological dilatation of the pupil\n* History or presence of proliferative retinopathy\n* History or presence of clinical significant macular oedema (CSME)\n* History or evidence of photocoagulation of the retina\n* Other retinal conditions which may mask assessment, eg, retinal vein occlusion\n* Positive micral dipstick test\n* Presence of secondary diabetes\n* Pregnant or lactating women or women of child bearing potential not practicing an adequate method of contraception\n* Need of treatment with ACE-inhibitor\n* Haemodynamically significant aortic or mitral valve stenosis\n* Known renal artery stenosis or kidney transplantation\n* Hypersensitivity to study drug\n* Severe concomitant disease which may interfere with the assessment of the patient, eg, malignancy, as judged by the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"55 Years","stdAges":["ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale","description":"Retinopathy progression was defined as the first occurrence of at least a 3-step increase in the ETDRS severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11). A generlized log-rank test was used to test difference between treatments.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":"0.034"},{"groupId":"OG001","value":"124","spread":"0.033"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With a Regression of Diabetic Retinopathy.","description":"Regression of diabetic retinopathy was defined as at least a 3 step improvement or a persistent 2-step improvement (confirmed in 2 consecutive photography sets) in the Early Treatment of Diabetic Retinopathy Study (ETDRS) severity scale. 3 steps were defined as either a 1-step change in one eye and a 2-step change in the other eye or as a 3-step change in one eye only. EDRTS is a scale with 11 steps (1-11).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"140","spread":"0.039"},{"groupId":"OG001","value":"139","spread":"0.039"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).","description":"Clinically Significant Macular Edema (CSME) and Proliferative Diabetic Retinopathy (PDR) are diagnosed via retinal photographs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110","spread":"0.03"},{"groupId":"OG001","value":"107","spread":"0.03"}]}]}]},{"type":"SECONDARY","title":"Rate of Change in Urinary Albumin Excretion Rate (UAER).","description":"An estimate of the slope from fitting a linear regression of log (UAER) over time (post-randimisation, yearly assessments) for each patient","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.569","spread":null},{"groupId":"OG001","value":"0.642","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":173,"n":951},"commonTop":["Hypotension"]}}}